ConductScience.org, home
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
API referenceFor AI assistants

Trial · NCT04236141

Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDPolatuzumab Vedotin Plus Bendamustine and Rituximab28
Overall StudySTARTEDPlacebo Plus Bendamustine and Rituximab14
Overall StudySafety PopulationPolatuzumab Vedotin Plus Bendamustine and Rituximab27
Overall StudySafety PopulationPlacebo Plus Bendamustine and Rituximab14
Overall StudyPharmacokinetic-Evaluable PopulationPolatuzumab Vedotin Plus Bendamustine and Rituximab27
Overall StudyPharmacokinetic-Evaluable PopulationPlacebo Plus Bendamustine and Rituximab0
Overall StudyImmunogenicity-Evaluable Population (Baseline Evaluable)Polatuzumab Vedotin Plus Bendamustine and Rituximab27
Overall StudyImmunogenicity-Evaluable Population (Baseline Evaluable)Placebo Plus Bendamustine and Rituximab14
Overall StudyImmunogenicity-Evaluable Population (Post-Baseline Evaluable)Polatuzumab Vedotin Plus Bendamustine and Rituximab24
Overall StudyImmunogenicity-Evaluable Population (Post-Baseline Evaluable)Placebo Plus Bendamustine and Rituximab0
Overall StudyIntent-to-treat PopulationPolatuzumab Vedotin Plus Bendamustine and Rituximab28
Overall StudyIntent-to-treat PopulationPlacebo Plus Bendamustine and Rituximab14
Overall StudyCOMPLETEDPolatuzumab Vedotin Plus Bendamustine and Rituximab0
Overall StudyCOMPLETEDPlacebo Plus Bendamustine and Rituximab0
Overall StudyNOT COMPLETEDPolatuzumab Vedotin Plus Bendamustine and Rituximab28
Overall StudyNOT COMPLETEDPlacebo Plus Bendamustine and Rituximab14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04236141/flow

API referenceFor AI assistants